Imaging myeloma and related monoclonal plasma cell disorders using MRI, low dose whole-body CT and FDG PET/CT

WITHOFS, Nadia; NANNI, C.; SIMONI, Paolo; FANTI, S.; BEGUIN, Yves; CAERS, Jo

doi:10.1007/s40336-015-0119-x

Request a copy

Article (Scientific journals)

Imaging myeloma and related monoclonal plasma cell disorders using MRI, low dose whole-body CT and FDG PET/CT

WITHOFS, Nadia; NANNI, C.; SIMONI, Paolo et al.

2015 • In Clinical and Translational Imaging, 3, p. 95-109

Peer reviewed

Permalink
https://hdl.handle.net/2268/177556

DOI
10.1007/s40336-015-0119-x

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

MM 2015 Clin Transl Imaging fulltext.pdf

Publisher postprint (3.81 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Myeloma; Imaging; PET; MRI; Staging; Prognosis

Abstract :

[en] A majority of multiple myeloma patients present with osteolytic bone lesions that can cause bone pain, fractures or hypercalcaemia. Correct identification of these lesions is important in the initial assessment of the disease. <br />Although the radiological skeletal survey is the gold standard to detect bone osteolytic lesions, it may miss small bone lesions or lesions located in the spine or pelvis due to the superimposed images of soft tissues. These limitations propelled newer imaging techniques such as positron emission tomography combined with computed tomography (PET/CT) and magnetic resonance imaging (MRI) in the diagnosis of multiple myeloma. In addition, 18F-fluorodeoxyglucose PET/CT and MRI have prognostic value and can be used to monitor disease. <br />This review discusses the additional value of PET/CT and MRI in the management of MM.

Disciplines :

Radiology, nuclear medicine & imaging
Oncology
Human health sciences: Multidisciplinary, general & others
Hematology

Author, co-author :

WITHOFS, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de médecine nucléaire et imagerie onco

NANNI, C.; ALMA MATER-UNIVERSITY OF BOLOGNA ANS S. ORSOLA-MALPIGHI HOSPITAL > DPT OF EXPERIMENTAL DIAGNOSTIC AND SPECIALTY MEDICINE > NUCLEAR MEDICINE UNIT

SIMONI, Paolo ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de radiodiagnostic

FANTI, S.; ALMA MATER-UNIVERSITY OF BOLOGNA AND S. ORSOLA-MALPIGHI HOSPITAL > DPT OF EXPERIMENTAL DIAGNOSTIC AND SPECIALTY MEDICINE > NUCLEAR MEDICINE UNIT

BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Imaging myeloma and related monoclonal plasma cell disorders using MRI, low dose whole-body CT and FDG PET/CT

Publication date :

20 March 2015

Journal title :

Clinical and Translational Imaging

ISSN :

2281-5872

eISSN :

2281-7565

Publisher :

Springer

Volume :

Pages :

95-109

Peer reviewed :

Peer reviewed

Available on ORBi :

since 27 January 2015

Statistics

Number of views

97 (33 by ULiège)

Number of downloads

10 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548.
Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK (2013) Smoldering multiple myeloma requiring treatment: Time for a new definition? Blood 122(26):4172–4181.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S (2013) Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: A systematic review. Br J Haematol 162(1):50–61.
Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, Beguin Y (2014) The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica 99(4):629–637.
Kyle RA (1975) Multiple myeloma: review of 869 cases. Mayo Clin Proc 50(1):29–40.
Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R (1992) Curability of solitary bone plasmacytoma. J Clin Oncol 10(4):587–590.
Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR (2009) Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 46(2):110–117.
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842–854.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420.
Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA (1990) Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood 75(4):823–830.
Child JA, Crawford SM, Norfolk DR, O’Quigley J, Scarffe JH, Struthers LP (1983) Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer 47(1):111–114.
Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84(6):2008–2011.
Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50(6):693–703.
Lecouvet FE, Vande Berg BC, Malghem J, Maldague BE (2001) Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 5(1):43–55.
Greenspan A (2000) Malignant bone tumours IIIn: Greenspan A, ed. Orthopedic radiology: A practical approach, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 697–700.
Hubner KF, Andrews GA, Hayes RL, Poggenburg JK Jr, Solomon A (1977) The use of rare-earth radionuclides and other bone-seekers in the evaluation of bone lesions in patients with multiple myeloma or solitary plasmacytoma. Radiology 125(1):171–176.
Wahner HW, Kyle RA, Beabout JW (1980) Scintigraphic evaluation of the skeleton in multiple myeloma. Mayo Clin Proc 55(12):739–746.
Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BGM (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23(9):1545–1556.
Terpos E, Moulopoulos LA, Dimopoulos MA (2011) Advances in imaging and the management of myeloma bone disease. J Clin Oncol 29(14):1907–1915.
Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92(1):50–55.
Collins CD (2004) Multiple myeloma. Cancer Imaging 4(Spec No A):S47–S53. doi:10.1102/1470-7330.2004.0010.
Wahlin A, Holm J, Osterman G, Norberg B (1982) Evaluation of serial bone X-ray examination in multiple myeloma. Acta Med Scand 212(6):385–387.
Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55(1):56–63.
Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, McHugh J, O’Connell M, O’Gorman P, Eustace SJ (2009) Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 38(3):225–236.
Lambert J, MacKenzie JD, Cody DD, Gould R (2014) Techniques and tactics for optimizing CT dose in adults and children: state of the art and future advances. J Am Coll Radiol 11(3):262–266.
Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, Gunther RW (2002) Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 178(6):1429–1436.
Shah LM, Hanrahan CJ (2011) MRI of spinal bone marrow: part I, techniques and normal age-related appearances. AJR Am J Roentgenol 197(6):1298–1308.
Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, Vande Berg BC (1999) Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 106(1):35–39.
Joffe J, Williams MP, Cherryman GR, Gore M, McElwain TJ, Selby P (1988) Magnetic resonance imaging in myeloma. Lancet 1(8595):1162–1163.
Lecouvet FE, Malghem J, Michaux L, Michaux JL, Lehmann F, Maldague BE, Jamart J, Ferrant A, Vande Berg BC (1997) Vertebral compression fractures in multiple myeloma. Part II. Assessment of fracture risk with MR imaging of spinal bone marrow. Radiology 204(1):201–205.
Van Gelderen WF, Al-Hindawi M, Gale RS, Steward AH, Archibald CG (1997) Significance of short tau inversion recovery magnetic resonance sequence in the management of skeletal injuries. Australas Radiol 41(1):13–15.
Diamond TH, Hartwell T, Clarke W, Manoharan A (2004) Percutaneous vertebroplasty for acute vertebral body fracture and deformity in multiple myeloma: A short report. Br J Haematol 124(4):485–487.
Lafforgue P, Dahan E, Chagnaud C, Schiano A, Kasbarian M, Acquaviva PC (1993) Early-stage avascular necrosis of the femoral head: MR imaging for prognosis in 31 cases with at least 2 years of follow-up. Radiology 187(1):199–204.
Moulopoulos LA, Dimopoulos MA (1997) Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 90(6):2127–2147.
Lee MJ, Kim S, Lee SA, Song HT, Huh YM, Kim DH, Han SH, Suh JS (2007) Overcoming artifacts from metallic orthopedic implants at high-field-strength MR imaging and multi-detector CT. Radiographics 27(3):791–803.
Song KD, Yoon YC, Park J (2013) Reducing metallic artefacts in post-operative spinal imaging: slice encoding for metal artefact correction with dual-source parallel radiofrequency excitation MRI at 3.0 T. Br J Radiol 86(1027):20120524.
Vande Berg BC, Lecouvet FE, Michaux L, Ferrant A, Maldague B, Malghem J (1998) Magnetic resonance imaging of the bone marrow in hematological malignancies. Eur Radiol 8(8):1335–1344.
Rahmouni A, Divine M, Mathieu D, Golli M, Dao TH, Jazaerli N, Anglade MC, Reyes F, Vasile N (1993) Detection of multiple myeloma involving the spine: Efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol 160(5):1049–1052.
Golfieri R, Baddeley H, Pringle JS, Souhami R (1990) The role of the STIR sequence in magnetic resonance imaging examination of bone tumours. Br J Radiol 63(748):251–256.
Mirowitz SA, Apicella P, Reinus WR, Hammerman AM (1994) MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images. AJR Am J Roentgenol 162(1):215–221.
Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M (2011) Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 196(6):W790–W795.
Messiou C, Giles S, Collins DJ, West S, Davies FE, Morgan GJ, Desouza NM (2012) Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol 85(1020):e1198–e1203.
Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, Davies FE, Morgan GJ, deSouza NM (2014) Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 271(3):785–794.
Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, Alexanian R, Libshitz HI (1992) Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 185(3):833–840.
Tertti R, Alanen A, Remes K (1995) The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 91(3):658–660.
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25(9):1121–1128.
van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM (2012) 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review. Cancer 118(8):1971–1981.
Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G, Cavo M, Lodi F, Pettinato C, Grassetto G, Franchi R, Gross MD, Fanti S (2008) 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo 22(4):513–517.
Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49(12):1928–1935.
Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M (2003) Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 18(5):841–845.
Salaun PY, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodere-Kraeber F (2008) FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica 93(8):1269–1271.
Barnwell J, Raptis CA, McConathy JE, Laforest R, Siegel BA, Woodard PK, Fowler K (2014) Beyond whole-body imaging: Advanced imaging techniques of PET/MRI. Clin Nucl Med 40(2):e88–e95.
Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068–2076.
Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U, Cavo M, Fanti S, Battista G, Salizzoni E (2012) Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease. Eur J Radiol 81(12):4013–4018.
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989–5995.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working G (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269–277.
Bianchi G, Anderson KC (2014) Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin 64(6):422–444.
Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8(8):479–491.
Vincent Rajkumar S (2014) Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999–1009.
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761–1767.
Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L (2012) Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med 53(12):1829–1835.
Sager S, Ergul N, Ciftci H, Cetin G, Guner SI, Cermik TF (2011) The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skelet Radiol 40(7):843–847.
Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, Van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B (2012) Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 98(1):71–78.
Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M, Koureas A, Migkou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Gika D, Koutoulidis V, Terpos E (2012) Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. Am J Hematol 87(9):861–864.
Anderson KC, Bensinger W, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung H, Gasparetto C, Godby K, Hernandez-Ilizaliturri F, Hofmeister C, Huff CA, Kassim A, Krishnan AY, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J (2014) Multiple myeloma, version 4.2015. J Natl Compr Canc Netw. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113(22):5412–5417.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106(3):812–817.
Vande Berg BC, Michaux L, Lecouvet FE, Labaisse M, Malghem J, Jamart J, Maldague BE, Ferrant A, Michaux JL (1997) Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology 202(1):247–251.
Durie BG, Waxman AD, D’Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43(11):1457–1463.
Hillengass J, Weber MA, Kilk K, Listl K, Wagner-Gund B, Hillengass M, Hielscher T, Farid A, Neben K, Delorme S, Landgren O, Goldschmidt H (2014) Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 28(1):174–178.
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590.
Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111(2):785–789.
Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31(34):4325–4332.
Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA (2013) Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27(4):947–953.
Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS, Jauch A, Neben K, Hose D, Egerer G, Weber MA, Delorme S, Goldschmidt H, Hillengass J (2014) Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 28(9):1902–1908.
Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78–85.
Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9):1606–1610.
Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, Berthon C, Terriou L, Coiteux V, Macro M, Decaux O, Facon T, Huglo D, Leleu X (2014) Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res 20(12):3254–3260.
Kim PJ, Hicks RJ, Wirth A, Ryan G, Seymour JF, Prince HM, Mac Manus MP (2009) Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 74(3):740–746.
Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R (1993) Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11(7):1311–1315.
Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, Dohner H, Bergmann L, Reske SN (2002) Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 29(3):361–366.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working G (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473.
Schulze M, Weisel K, Grandjean C, Oehrlein K, Zago M, Spira D, Horger M (2014) Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study. AJR Am J Roentgenol 202(1):170–179.
Daldrup-Link HE, Henning T, Link TM (2007) MR imaging of therapy-induced changes of bone marrow. Eur Radiol 17(3):743–761.
Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, Yamamura J, Adam G, Stubig T, Kroger N, Weber C (2012) Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol 22(9):2007–2012.
Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R, Hose D, Delorme S, Goldschmidt H, Neben K (2012) Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 97(11):1757–1760.
Lin C, Luciani A, Belhadj K, Deux JF, Kuhnowski F, Maatouk M, Beaussart P, Cuenod CA, Haioun C, Rahmouni A (2010) Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 254(2):521–531.
Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21(8):1713–1718.
Dutoit JC, Vanderkerken MA, Verstraete KL (2013) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. Eur J Radiol 82(9):1444–1452.
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, International Myeloma Workshop Consensus P (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117(18):4701–4705.
Hillengass J, Landgren O (2013) Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma 54(7):1355–1363.
Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour heterogeneity in the clinic. Nature 501(7467):355–364.
Hillengass J, Zechmann C, Bauerle T, Wagner-Gund B, Heiss C, Benner A, Ho A, Neben K, Hose D, Kauczor HU, Goldschmidt H, Delorme S, Moehler T (2009) Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 15(9):3118–3125.
Song MK, Chung JS, Lee JJ, Min CK, Ahn JS, Lee SM, Shin DY, Bae SH, Hong J, Lee GW, Lee IS, Shin HJ (2014) Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. Br J Haematol 165(6):777–785.